Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy
暂无分享,去创建一个
R. D'Amato | J. Folkman | T. Udagawa | Antonio Fernández | E. Achilles | TATURO UDAGAWA | ANTONIO FERNANDEZ | EIKE‐GERT ACHILLES | JUDAH FOLKMAN | ROBERT J. D'AMATO | Antonio Fernández
[1] H. Kleinman,et al. Basement membrane and the SIKVAV laminin-derived peptide promote tumor growth and metastases , 1991, Cancer and Metastasis Reviews.
[2] R. Kerbel,et al. The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor , 2004, Angiogenesis.
[3] J. McDonald,et al. Occult malignant astrocytoma of pons with extracranial metastasis to bone prior to craniotomy , 2004, Acta Neuropathologica.
[4] J. Klijn,et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.
[5] J. Folkman,et al. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. , 2001, Journal of the National Cancer Institute.
[6] C. Caldas,et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. , 2001, The New England journal of medicine.
[7] R. D'Amato,et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. , 2001, Journal of the National Cancer Institute.
[8] R. Kerbel,et al. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. , 2000, The journal of investigative dermatology. Symposium proceedings.
[9] J. Niloff,et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] O. Brison,et al. Regulation of FGF-3 Gene Expression in Tumorigenic and Non-tumorigenic Clones of a Human Colon Carcinoma Cell Line* , 2000, The Journal of Biological Chemistry.
[11] O. Volpert,et al. An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[12] S. R. Datta,et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. , 1999, Science.
[13] D. Fraker,et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. , 1999, Radiology.
[14] L. Chin,et al. Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.
[15] J. Califano,et al. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. , 1999, Journal of the National Cancer Institute.
[16] H. Matsuoka,et al. [Disseminated carcinomatosis of the bone marrow occurring 11 years after subtotal gastrectomy for gastric cancer]. , 1998, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[17] J. Arbiser,et al. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma , 1998, Oncogene.
[18] J. Folkman,et al. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. , 1998, Archives of dermatology.
[19] P. Pour,et al. Histologic and biologic patterns of microscopic pancreatic ductal adenocarcinomas detected incidentally at autopsy , 1998, Cancer.
[20] R. Kerbel,et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[21] Y. Oshika,et al. Is xenotransplantability of human colon cancers in SCID mice affected by angiogenic factors? , 1998, Journal of the National Cancer Institute.
[22] J. Folkman,et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[23] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[24] R. Kerbel,et al. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. , 1996, European journal of cancer.
[25] N. Sheibani,et al. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. , 1996, Cancer letters.
[26] A. Multani,et al. Non-random primary and secondary chromosomal abnormalities in human gastric cancers. , 1996, Anticancer research.
[27] D. Hanahan,et al. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. , 1995, Molecular endocrinology.
[28] R. Kerbel,et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.
[29] S. Koscielny,et al. Re: Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.
[30] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[31] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[32] Erwin G. Van Meir,et al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.
[33] R. Demicheli,et al. Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.
[34] F Vignon,et al. [Growth factors and cancer]. , 1994, Journal de gynecologie, obstetrique et biologie de la reproduction.
[35] W C Black,et al. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. , 1993, The New England journal of medicine.
[36] K. Kinzler,et al. The multistep nature of cancer. , 1993, Trends in genetics : TIG.
[37] H. Seigler,et al. Relationship between disease-free interval and survival in patients with recurrent melanoma. , 1992, Archives of surgery.
[38] M. L. Le Beau,et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[39] D. Hanahan,et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.
[40] H. Levin,et al. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer , 1989, Cancer.
[41] J. A. Andersen,et al. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. , 1987, British Journal of Cancer.
[42] K. Franssila,et al. Occult papillary carcinoma of the thyroid. A “normal” finding in finland. A systematic autopsy study , 1985, Cancer.
[43] Cori Bargmann,et al. Mechanism of activation of a human oncogene , 1982, Nature.
[44] L. Woolner,et al. Occult papillary carcinoma of the thyroid. , 1980, Archives of surgery.
[45] A. Billiau,et al. Human Interferon: Mass Production in a Newly Established Cell Line, MG-63 , 1977, Antimicrobial Agents and Chemotherapy.
[46] J. Fogh,et al. New Human Tumor Cell Lines , 1975 .
[47] J. Folkman,et al. TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.
[48] Beckwith Jb,et al. IN SITU NEUROBLASTOMAS: A CONTRIBUTION TO THE NATURAL HISTORY OF NEURAL CREST TUMORS. , 1963 .
[49] J. Beckwith,et al. IN SITU NEUROBLASTOMAS: A CONTRIBUTION TO THE NATURAL HISTORY OF NEURAL CREST TUMORS. , 1963, The American journal of pathology.
[50] M. Batts,et al. OSTEOGENIC SARCOMA: AN ANALYSIS OF EIGHTY CASES , 1941 .